Enhanced radiation damage of tumor vasculature by mTOR inhibitors
- PMID: 15940265
- DOI: 10.1038/sj.onc.1208715
Enhanced radiation damage of tumor vasculature by mTOR inhibitors
Abstract
It is known that radiation activates the phosphoinositol-3 kinase (PI3K)/Akt pathway and that inhibition of PI3K or Akt sensitizes tumor vasculature to radiotherapy. Mammalian target of rapamycin (mTOR) is a downstream target of Akt, and we hypothesized that irradiation activates mTOR signaling in both glioma and endothelial cells (ECs) and that radiosensitization results from inhibiting mTOR signaling. mTOR inhibitors, rapamycin and RAD001 (everolimus) were found to radiosensitize vascular ECs, but failed to sensitize glioma cells as determined by clonogenic assay. Therefore, we investigated the anti-angiogenic effects of mTOR inhibitors. Increased phospho-mTOR protein was detected in irradiated human umbilical vein endothelial cells (HUVEC), but not in GL261 glioma cells. Phospho-S6, a biomarker for mTOR signaling, was also found to be induced following irradiation in HUVEC and this effect was inhibited by PI3K or mTOR inhibitors. Significant increase in cleaved caspase 3 was detected when Rad001 was combined with radiation. Endothelial tube formation was significantly diminished following treatment with rapamycin and 3 Gy of radiation. Histological sections of GL261 tumors from mice showed a greatly reduced vascular density when treated with RAD001 and radiation. Power Weighted Doppler of glioma xenografts in mice showed a significant reduction in vasculature and blood flow compared with mice treated with 3 Gy or RAD001 alone. We conclude that irradiation activates mTOR signaling in vascular endothelium and that rapamycin and RAD001 increased apoptosis of ECs in response to radiation. To the authors' best knowledge this is the first study which demonstrates that mTOR inhibitors may be a way to target the vasculature by radiosensitizing the vascular endothelium resulting in better tumor control as seen in experiments demonstrating increased tumor growth delay in mice treated with rapamycin with radiation compared with mice treat with either treatment alone. We conclude that mTOR inhibitors have increased efficacy as antiangiogenics when combined with radiation.
Similar articles
-
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.Clin Cancer Res. 2008 Feb 1;14(3):892-900. doi: 10.1158/1078-0432.CCR-07-0955. Clin Cancer Res. 2008. PMID: 18245553
-
Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.Clin Cancer Res. 2009 Jan 15;15(2):589-96. doi: 10.1158/1078-0432.CCR-08-1019. Clin Cancer Res. 2009. PMID: 19147764
-
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17. Clin Cancer Res. 2009. PMID: 19223496
-
Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.J BUON. 2006 Jul-Sep;11(3):267-76. J BUON. 2006. PMID: 17309148 Review.
-
The pleiotropic effects of mTor inhibitors.J Nephrol. 2004 Nov-Dec;17(6):762-8. J Nephrol. 2004. PMID: 15593048 Review.
Cited by
-
Novel biological strategies to enhance the radiation therapeutic ratio.Radiat Oncol J. 2018 Sep;36(3):172-181. doi: 10.3857/roj.2018.00332. Epub 2018 Sep 30. Radiat Oncol J. 2018. PMID: 30309208 Free PMC article.
-
The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence.PLoS One. 2013 Nov 11;8(11):e79658. doi: 10.1371/journal.pone.0079658. eCollection 2013. PLoS One. 2013. PMID: 24244540 Free PMC article.
-
Mammalian target of rapamycin and head and neck squamous cell carcinoma.Head Neck Oncol. 2011 Apr 24;3:22. doi: 10.1186/1758-3284-3-22. Head Neck Oncol. 2011. PMID: 21513566 Free PMC article. Review.
-
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.Neuro Oncol. 2018 Apr 9;20(5):666-673. doi: 10.1093/neuonc/nox209. Neuro Oncol. 2018. PMID: 29126203 Free PMC article. Clinical Trial.
-
Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.Paediatr Drugs. 2012 Feb 1;14(1):51-60. doi: 10.2165/11207730-000000000-00000. Paediatr Drugs. 2012. PMID: 22136276 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous